As of 8:10 PM 05/23/13 All times are local (Market data is delayed by at least 15 minutes).
Executive Profile*
Noubar B. Afeyan Ph.D.Founder, Director, Chairman of Compensation Committee and Member of Nominating & Governance Committee, BG Medicine, Inc. | |
| Age | Total Calculated Compensation | This person is connected to 174 board members in 18 different organizations across 23 different industries.
See Board Relationships |
| 49 | $67,266
|
Background*
Dr. Noubar B. Afeyan, Ph.D. is a Co-Founder, Managing Partner, and Chief Executive Officer at Flagship Ventures. He is a Co-Founder of Adnexus Therapeutics Inc. and has been its Treasurer since October 2002. He is Co-Founder and Chairman of Moderna Therapeutics, Inc. He founded Joule Biotechnologies and serves as the Chairman of the Board. Dr. Afeyan is a Co-Founder at YerazArt. He co-founded Helicos BioSciences Corporation and served as its Chairman until October 2007. ... He has been a Special Partner at OneLiberty Ventures since 1999. He founded LS9, Inc. in 2005. Dr. Afeyan is a Co-Founder and Chairman of Joule Unlimited, Inc. He is the Founder of BG Medicine, Inc. and served as its Executive Chairman until July 2011. He served as the President and Chief Executive Officer at NewcoGen Group. In addition, he is the Managing General Partner at AGTC Funds. He co-founded Theracrine, Inc. in 2010 and served as its Chairman. Dr. Afeyan was a Member of the founding team, Director and investor in several successful ventures including Antigenics since 1988. He was the President, Chief Executive Officer at Applied Genomic Technology Capital Funds. Dr. Afeyan is a recognized technologist, entrepreneur, and venture capitalist. He has founded and helped build over 25 successful life science and technology startups during the past two decades. Dr. Afeyan served as the Senior Vice President and Chief Business Officer at Applera Corp. and initiated and oversaw the creation of Celera Genomics. He served as the Chief Executive Officer at PerSeptive Biosystems, Inc. from June 1992 to 1997. Dr. Afeyan served as the President at Perseptive Biosystems Inc. from June 1992 to July 1996, Executive Vice President of Technology and Operations, from 1987 to 1992, Chief Technical Officer, from 1987 to 1993, and Treasurer, from 1987 to 1995. He served as the President at PerSeptive Technologies II Corp. Currently; he serves on a number of public and private company boards. He serves as Chairman and Director of Ensemble Therapeutics Corporation. He served as Chairman and Director of T2 Biosystems, Inc. and Selventa, Inc. He served as the Chairman of Genstruct. Dr. Afeyan served as Chairman of the Board of LS9, Inc. until August 15, 2012. From 1996 to 1997, he also served as the Chairman of the Board of ChemGenics Pharmaceuticals and was also the Member of the founding team, Director and investor. He has been a Director of BG Medicine, Inc. since 2000. He is a Director of BIND Biosciences, Breathable Foods, Ensemble Discovery and Essentient Inc., Genstruct. He serves as a Director of Pronutria, AeroDesigns, Inc., Eleven Biotherapeutics Inc. and Bioplex Systems. He has been Director of Affinnova, Inc. He served as the Chairman and Director of Codon Devices, Inc. Dr. Afeyan is engaged as an Advisor and Board Observer with Flagship portfolio companies including BIND Biosciences, Mascoma, and Resolvyx. He serves as a Director of LS22, Inc. and WikiCell Designs, Inc. Dr. Afeyan has been a Director of Beyond Genomics, Compound Therapeutics, Inc. and engeneOS. He has been Director of Adnexus Therapeutics Inc. since 2002. He serves as a Member of Advisory Board at Whitehead Institute For Bio-Medical Research and Harvard-MIT Division of Health Sciences and Technology. He serves as a Member of the Board of Overseers at Boston University. He has been Director of Philips Solid-State Lighting Solutions, Inc., since 1998. He serves on the Board of AmeriaBank. Dr. Afeyan has also been a founding investor and active Director and Advisor for several other high-tech startups including Lifetecnet. He serves as Director of LS9, Inc. He served as a Director of Helicos BioSciences Corporation until August 24, 2012 and served as its Lead Independent Director from October 2007 to August 2012. He served as a Member of Scientific Advisory Board of Epitome Biosystems, Inc. He served as Director of Fabric Networks Inc. He served as a Director of PerSeptive Technologies II Corp., Exact Sciences Corporation and Perseptive Biosystems Inc. Dr. Afeyan was a Director of Color Kinetics Inc. and was also a Member of the founding team and investor. He served as a Director of Adaptive Therapeutics, Inc. and Blue Ripple, Inc. Dr. Afeyan served as a Director of Cellular Genomics Inc., CGI Pharmaceuticals, Inc. and Perseptive Biosystems Inc. He served as Director of Agenus Inc., since 1998. Dr. Afeyan is the Co-Founder and a Director of National Competitiveness Council of Armenia and started a project called Armenia 2020. He currently serves as Vice-chair of the Global Agenda Council on Emerging Technologies of the World Economic Forum. Dr. Afeyan is a Member of the Board of Overseers of Boston University, the Board of Visitors of Boston University School of Medicine, and the Board of Overseers of the Boston Symphony Orchestra. In addition, he is a Member of several Advisory Boards including the Whitehead Institute at MIT, the Harvard-MIT Division of Health Sciences and Technology (HST), Yale Climate & Energy Initiative, and the SKOLKOVO School of Management in Moscow. Dr. Afeyan served as a Technology Transfer Officer for the Biotechnology Process Engineering Center at the Massachusetts Institute of Technology. He was honored in 2008 as one of the Ellis Island Medal of Honor recipients, recognizing his contributions to the local community as well as his extensive role in supporting long range visions for the country of Armenia, its business environment and culture, and world-wide understanding and awareness of Armenian issues. Dr. Afeyan also received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. He has authored numerous publications and patents, is a frequent guest speaker at technology forums throughout the country, and is a Senior Lecturer at Massachusetts Institute of Technology's Sloan School of Management, where he has taught the M.B.A. program’s primary entrepreneurship course since 2000. Dr. Afeyan holds a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology in 1987 and a B.S. degree in Chemical Engineering from McGill University.
Corporate Headquarters*
610 Lincoln Street North
Waltham, Massachusetts 02451
United States
Phone: 781-890-1199
Fax: 781-895-1119
Board Members Memberships*
Former Director Former Director Director Former Director Former Chairman of the Board Director Former Director Chairman Former Chairman Co-Founder and Director Former Chairman Director Co-Founder and Chairman Director Co-Founder Director Co-Founder and Chairman Director Director Director Member of Board 1987-N/A Former Chairman, Chief Executive Officer, President of PerSeptive Technologies II Corporation and Director of PerSeptive Technologies II Corporation 1998-Present Director and Chairman of Compensation Committee 1998-N/A Former Director, Member of Compensation Committee and Member of Corporate Governance & Nominating Committee 2000-Present Founder, Director, Chairman of Compensation Committee and Member of Nominating & Governance Committee 2002-Present Co-founder, Treasurer and Director 2003-2012 Co-Founder
Education*
PhD 1987 Massachusetts Institute of Technology BS McGill University
Other Affiliations*
|
Annual Compensation*
There is no Annual Compensation data available.
Stock Options*
| Exercisable Options | 4,205 | | Unexercisable Options | 4,205 | | Total Number of Options | 8,410 |
Total Compensation*
| Total Annual Cash Compensation | $34,250 | | Total Calculated Compensation | $67,266 |
|
*Data is at least as current as the most recent Definitive Proxy.
